Shares of Astrana Health, Inc. (NASDAQ:ASTH – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $45.00.
Several brokerages have recently issued reports on ASTH. Zacks Research upgraded shares of Astrana Health from a “strong sell” rating to a “hold” rating in a research note on Wednesday, March 11th. Needham & Company LLC raised their price target on shares of Astrana Health from $30.00 to $41.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Barclays upgraded shares of Astrana Health from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $37.00 to $50.00 in a research note on Tuesday, May 26th. Truist Financial raised their price target on shares of Astrana Health from $38.00 to $47.00 and gave the stock a “buy” rating in a research note on Thursday, May 14th. Finally, Robert W. Baird set a $45.00 price target on shares of Astrana Health in a research note on Friday, May 8th.
View Our Latest Analysis on ASTH
Institutional Investors Weigh In On Astrana Health
Astrana Health Price Performance
ASTH opened at $38.29 on Friday. The firm has a market cap of $2.13 billion, a P/E ratio of 62.77 and a beta of 1.00. The firm has a 50-day moving average of $33.98 and a 200 day moving average of $27.19. The company has a debt-to-equity ratio of 1.20, a quick ratio of 1.35 and a current ratio of 1.35. Astrana Health has a fifty-two week low of $18.08 and a fifty-two week high of $39.93.
Astrana Health (NASDAQ:ASTH – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.74 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.45. The company had revenue of $965.10 million during the quarter, compared to analyst estimates of $949.21 million. Astrana Health had a net margin of 0.86% and a return on equity of 9.22%. The firm’s revenue for the quarter was up 55.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.42 earnings per share. On average, research analysts expect that Astrana Health will post 1.25 EPS for the current year.
About Astrana Health
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.
Read More
- Five stocks we like better than Astrana Health
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
- Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
- Crypto Winter Is Here: 3 Stocks To Put On Ice This Summer
Receive News & Ratings for Astrana Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrana Health and related companies with MarketBeat.com's FREE daily email newsletter.
